Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target increased by Barclays from $40.00 to $42.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms also recently issued reports on TEVA. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Weiss Ratings raised Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $42.22.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $36.78 on Wednesday. Teva Pharmaceutical Industries has a twelve month low of $17.33 and a twelve month high of $37.39. The firm’s fifty day simple moving average is $33.52 and its 200-day simple moving average is $32.99. The firm has a market capitalization of $42.87 billion, a price-to-earnings ratio of 61.31, a PEG ratio of 3.91 and a beta of 0.86. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Equities analysts forecast that Teva Pharmaceutical Industries will post 1.96 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares of the company’s stock, valued at approximately $2,237,676.10. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.54% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth raised its holdings in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Franklin Resources Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $255,000. Flow Traders U.S. LLC acquired a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $238,000. Finally, Cerity Partners LLC lifted its position in Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after buying an additional 1,291 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.